A Safety Study of Pentoxifylline for the Treatment of Anemia

Stopped early · Phase 2

Conditions studied: End Stage Renal Disease

In brief

Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patients with anemia. This study will examine the use of pentoxifylline for the treatment of anemia in chronic kidney disease.

Key facts

Study ID

NCT01102218

Run by

Fresenius Medical Care North America

People needed

48

Starts

2010-08-01

Expected to finish

2012-01-01

Last updated by the study team

2012-03-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, aged ≥18 years;
• Able to comply with the study procedures and medication;
• Written informed consent given;
• On a stable in-center hemodialysis regimen (at least 3 times per week) for ≥ 12 weeks prior to screening;
• Subject must have been on a stable (< 25% change) erythropoietin dose with an average of ≥ 15,000 and <55,000 units/week of treatment for ≥ 14 days prior to screening visit;
• Two hemoglobin measurements must meet the following criteria: (1) Taken ≥ 2 weeks apart; (2) Between 10 and 12 g/dL, inclusive; (3) Within 1 g/dL of each other; and (4) Occurred within 30 days prior to screening visit;
• If subject is a female and of childbearing potential (pre-menopausal and not surgically sterile), subject is willing to use an effective contraceptive method throughout study, which includes abstinence, barrier methods, hormones, or IUDs;
• Life expectancy of 12 months or greater;
• Most recent single pool Kt/V ≥1.2, taken within 45 days prior to screening visit;
• Stable nutrition status with all albumin levels ≥ 3.0 g/dL within the 30 days prior to screening visit.

You may not qualify if…

• Participation in any clinical trial using an investigational product or device during the 30 days preceding the Screening Visit;
• Currently undergoing nocturnal hemodialysis;
• A significant history of alcohol, drug or solvent abuse in the opinion of the investigator;
• Serum iPTH > 800 pg/mL within 90 days prior to screening visit;
• Dysrhythmia or severe cardiac disease: CHF Class III-IV; unstable cardiovascular diagnosis (for example MI, CABG, PTCA, CVA, and TIA) within 90 days prior to screening visit;
• Significant concurrent liver disorder [Aspartate transaminase (AST) or alanine transaminase (ALT) values > 3 times upper limit of normal (ULN) within 30 days prior to screening];
• Platelet count < 130x109 within 30 days prior to screening visit or on the day of the screening visit;
• Known hypersensitivity to, or intolerance of, Pentoxifylline or other methylxanthines, such as caffeine, theophylline or theobromine;
• Currently taking pentoxifylline, warfarin, theophylline, aminophylline, dyphylline, or oxtriphylline;
• Absolute or functional iron deficiency [transferrin saturation (TSAT) <20%] within 45 days prior to screening;
• Recent or severe hemorrhage per PI discretion;
• Significant bleeding episode or prolonged bleeding from dialysis access per PI judgment within the 3 months prior to screening;
• Melatonin treatment, androgen therapy or blood transfusion within 30 days prior to screening;
• Vitamin C therapy at dose greater than 100 mg/day or at a dose which has changed within the last 3 months;
• Current active cancer (excluding basal cell carcinoma of the skin);
• Poorly controlled hypertension per PI judgment within 4 weeks prior to screening;
• Known HIV positive status;
• Significant GI disorders where absorption of an oral medication might, in the opinion of the Investigator, be impaired;
• Anticipated live donor kidney transplant or any other planned major surgery over the study duration;
• History of poor adherence to hemodialysis or medical regimen;
• Any active clinically significant infection or evidence of an underlying infection;
• Currently on immunosuppressive drug regimen other than a stable, low dose of steroids, per PI judgment;
• Any disease or condition, physical or psychological that, in the opinion of the investigator, would compromise the safety of the subject or the likelihood of achieving reliable results or increase the likelihood of the subject being withdrawn.

Where it is running

• Fresenius Medical Care North America — Chicago, Illinois, United States
• Fresenius Medical Care North America — Kalamazoo, Michigan, United States
• Fresenius Medical Care North America — Brookhaven, Mississippi, United States
• Fresenius Medical Care North America — Tupelo, Mississippi, United States
• Fresenius Medical Care North America — City of Saint Peters, Missouri, United States
• Fresenius Medical Care North America — Saint Ann, Missouri, United States
• Fresenius Medical Care North America — Las Vegas, Nevada, United States
• Fresenius Medical Care North America — Columbia, Tennessee, United States
• Fresenius Medical Care North America — Irving, Texas, United States
• Fresenius Medical Care North America — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.